An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 16, 2021

Primary Completion Date

March 2, 2022

Study Completion Date

March 2, 2022

Conditions

HyperuricemiaGoutChronic Kidney Diseases

Interventions

DRUG

ALLN-346

ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration

DRUG

Placebo

Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules

Trial Locations (1)

Celerion, Tempe